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ABSTRACT 
Recent data have suggested a strong possible link between Type 2 Diabetes Mellitus and Alzheimer’s disease 
(AD), although exact mechanisms linking the two are still a matter of research and debate. Interestingly, both are 
diseases with high incidence and prevalence in later years of life. The link appears so strong that some scientists 
use Alzheimer’s and Type 3 Diabetes interchangeably. In depth study of recent data suggests that the anti diabet-
ic drugs not only have possible role in treatment of Alzheimer’s but may also arrest the declining cognitive func-
tions associated with it. The present review gives an insight into the possible links, existing therapeutics and 
clinical trials of anti diabetic drugs in patients suffering from AD primarily or as co-morbidity. It may be con-
cluded that the possible beneficial effects and usefulness of the current anti diabetic drugs in AD cannot be ne-
glected and further research is required to achieve positive results. Currently, several drug trials are in progress 
to give conclusive evidence based data.  
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PPARγ = Peroxisome proliferator activated receptor gamma; GLP-1 = Glucagon-like peptide-1;  
DPP-4 = Dipeptidyl peptidase-4; SAMP8 = Senescence-accelerated prone;  
SGLTs = Sodium glucose co-transporters 
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INTRODUCTION 
One of the most common causes of pro-
gressive dementia in elderly population 
worldwide is Alzheimer’s disease (AD). Ex-
act pathophysiological processes resulting in 
progressive decline of cognitive functions 
still remain unclear (Kochanek et al., 2011).  
It is fascinating to know that pancreas 
which is highly innervated organ shares 
some similarities with brain at molecular 
(mainly transcriptome and proteome) levels 
(Allam et al., 2006). Many studies world-
wide have shown that Type 2 diabetes melli-
tus (T2DM) is a risk factor for AD (Whitmer 
et al., 2008; Biessels et al., 2008; Messier 
and Gagnon, 2009). Recent epidemiological, 
clinical and pathological data suggests pos-
sible link between T2DM and AD (Akter et 
al., 2011; Priyadarshini et al., 2012; Park, 
2011). AD and T2DM share several molecu-
lar processes suggesting possible common 
pathophysiology. Insulin dysfunction and 
hyperglycemia in diabetes possibly effects 
synaptic plasticity, learning and memory 
which may lead to AD (Akter et al., 2011; 
Exalto et al., 2012). Abnormalities in various 
biochemical and physiological pathways in-
volved in cell growth, cell differentiation, 
cellular repair mechanisms, energy metabo-
lism and glucose utilization could also give 
rise to AD (Li and Holscher, 2007). In the 
scenario of ever increasing burden of pro-
gressive debilitating diseases like DM and 
AD with possible common links the silver 
lining appears to be that “drugs used in 
treatment of one could effectively be used in 
the treatment of linked disease”. This novel 
idea holds true for other diseases sharing 
common pathophysiological processes. To 
the best of our knowledge, very few reviews 
are presented based on this idea. The present 
communication will focus on various trials 
of ‘Antidiabetic’ drugs (ADD), acting as 
suitable candidates in the treatment of both 
Diabetes as well as AD. Schematic represen-
tation of anti-diabetic drugs as therapeutic 
agents in neurological disorders has been 
shown in Figure 1. 
 
 
Figure 1: Schematic representation of anti-
diabetic drugs as therapeutic agents in neurolog-
ical disorders 
 
ANTI-DIABETIC DRUGS AGAINST AD 
Insulin 
Neuronal cell loss, neurofibrillary tangle 
(insoluble twisted fibers consisting primarily 
of the altered Tau protein) deposition inside 
cell, formation of Amyloid β (Aβ) (39-to-43 
peptide originating from the sequential en-
zymatic cleavage of the larger trans-
membrane protein called Amyloid Precursor 
Protein) plaque in the spaces among neurons 
and in the walls of blood vessels are micro-
scopic features of AD (Wisniewski and 
Frackowiak, 1998). Accumulation of Aβ is 
implicated in the pathogenic cascade (Hardy 
and Allsop, 1991). In the last decade many 
observations confirm that small Aβ oligo-
mers (Aβ-Derived Diffusible Ligands (AD-
DLs)) aggregates are more dangerous and 
toxic as compared to large aggregates 
(Picone et al., 2009). The accumulation of 
these aggregates triggers a variety of re-
sponses detrimental to neuron plasticity and 
memory viz oxidative stress, loss of spines 
and receptors (De Felice et al., 2009).  
Many researches since early 21st century 
have highlighted the possible links between 
AD and insulin signaling (chiefly insulin re-
sistance) associated with T2DM (Ronnemaa 
et al., 2008; Di Carlo et al., 2010). The link 
appears so strong that AD is often consid-
ered neuroendocrine disorder referred as 
“Diabetes Type 3” or “Brain Diabetes” 
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(Steen et al., 2005). It has been reported 
(Zhao et al., 2008) that insulin protects cul-
tured rat neurons against Aβ induced toxici-
ty. It has been shown experimentally that Aβ 
competes with insulin for the receptor bind-
ing thereby decreasing receptor auto phos-
phorylation (Carrotta et al., 2006). Insulin 
reduces toxic effects of Aβ by inhibiting fi-
brillar growth (Rensink et al., 2004). Due to 
their ability to regulate the mutual binding 
site abundance Insulin and ADDLs maintain 
competitive balance between synapse sur-
vival and degeneration. Thus with age relat-
ed progressive decline in brain insulin sig-
naling equilibrium is tilted in favor of AD-
DLs (De Felice et al., 2009). Newer drugs 
with ability to maintain the equilibrium 
could revolutionize the existing treatments 
available for Alzheimer’s and progressive 
cognitive function decline.  
There is substantive data available which 
gives insight into the possible protective role 
of insulin against Aβ toxicity at the molecu-
lar level. Insulin influences the cell viability 
by inhibiting the pro apoptotic pathways (Di 
Carlo et al., 2010). Deposition of Amyloid 
fibrils in pancreatic islets results in oxidative 
stress which in turn up regulates apoptosis of 
β cells (Allam et al., 2006). In contrast insu-
lin is shown to reduce oxidative stress by ac-
tivating serine-threonine kinase Akt signal-
ing pathway which in turn influences several 
proteins involved in apoptosis; survival is al-
so enhanced by insulin by shuttling Akt into 
various sub cellular compartments (Lee et 
al., 2009; Picone et al., 2011). Due to afore-
mentioned evidences and researches it is 
clear that decrease in insulin signaling with 
age could lead to AD and this knowledge in 
turn could be utilized to use insulin as thera-
peutics in AD. In fact many trials have been 
done in the past to completely / partially ar-
rest or slow the progression of AD using in-
sulin but the conventional methods available 
for administration of insulin in diabetics 
have potential risks in the AD patients, thus 
alternate routes are being explored. Intra na-
sal Insulin proved beneficial in dementia as-
sociated with AD, probably by changing Aβ 
42 levels and Tau protein-to-Aβ 42 ratios in 
cerebrospinal fluid (Craft et al., 2012). But 
the treatment is associated with certain side 
effects like irritation, nasal mucosa damage 
(Nolte et al., 1990) and increase in blood 
pressure (Cernea and Raz, 2006). The asso-
ciated side effects can be reduced by deliver-
ing insulin directly to the brain which re-
quires overcoming of blood brain barrier 
(BBB). 
 
INSULIN SENSITIZERS 
Biguanides (Metformin) 
Metformin (N, N dimethyl imidodi car-
bonimidic diamide) (Figure 2) is an orally 
active biguanide that has glucose lowering 
effects (suppress gluconeogenesis in liver), 
decreases insulin resistance, potentiates insu-
lin action and increases insulin sensitivity of 
liver and skeletal muscle via AMP-activated 
protein kinase (AMPK) (Zang et al., 2004; 
Hilder et al., 2005). AMPK acts as central 
regulator of lipid and glucose metabolism 
and upon activation increases insulin sensi-
tivity through interactions with a multiple in-
tracellular targets like Mammalian Target of 
Rapamycin, p38 Mitogen-Activated Protein 
Kinases, and Protein Kinase C. Conclusive 
data on the penetration of metformin and po-
tential effects in human CNS is lacking but 
studies in rodents have shown that metfor-
min does cross the BBB and activates 
AMPK in central nervous system (CNS) tis-
sue (Łabuzek et al., 2010; Nath et al., 2009). 
Experimental models have shown that Met-
formin provides neuroprotection via variety 
of mechanisms like reducing phosphoryla-
tion of tau protein in cortical neurons (Kick-
stein et al., 2010), prevention of apoptotic 
cell death in primary neurons (El-Mir et al.,  
 
 
Figure 2: Structure of Metformin 
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2008), by improving oxygen-glucose depri-
vation induced neuronal injury and thus en-
hancing survival of neurons (Mielke et al., 
2006). Similarly, various other studies have 
talked about the potential benefits of treat-
ment with metformin. Hwang and colleagues 
(2010) reported that treatment of Zucker dia-
betic fatty rat with metformin normalized the 
reduction of cell proliferation and neuroblast 
differentiation in hippocampal dentate gyrus. 
Gupta et al., (2011) reported an increase in 
insulin action which in turn prevented mo-
lecular and pathological characteristics asso-
ciated with AD in a cell cultured model of 
insulin resistance (induced by chronic expo-
sure of mouse neuroblastoma cell line, Neu-
ro-2a (N2A) to insulin) upon exposure to 
metformin. Increased neuronal viability was 
reported in an in vitro model of ischemia af-
ter treatment with metformin (Mielke et al., 
2006). Thus, metformin may prove benefi-
cial in reducing neuropathy and neuronal cell 
injury associated with hyperglycemia in dia-
betes. Interestingly, a Taiwanese clinical 
study conducted in human subjects found 
that the use of metformin significantly de-
creases the risk of dementia (Hsu et al., 
2011). Further clinical trials based on the 
above information and experimental designs 
could prove to be beneficial. 
Effects of metformin on Beta-site amy-
loid precursor protein cleaving enzyme-1/β-
secretase (BACE-1) in experimental models 
have also generated interest of researchers. 
BACE-1 is the major protease of amyloid 
precursor protein pathway which generates 
and accumulates Aβ in brain (levels directly 
correlate with pathogenesis of AD). Novel 
inhibitors by directly targeting BACE-1 
could reduce levels of Aβ in brain (Kirpich-
nikov et al., 2002; Knowler et al., 2002). In-
terestingly, treatment with the ADD metfor-
min decreases BACE1 protein expression 
and activity, thereby reducing it’s cleavage 
product Aβ (Gupta et al., 2011). Similarly, 
Chen and colleagues (2009) observed low 
Aβ production in culture medium in presence 
of insulin (reduction could further be en-
hanced by addition of metformin) as com-
pared to increased BACE1 mRNA levels, 
protein levels and Aβ production in the cul-
ture devoid of insulin.  
Other area of interest is role of metfor-
min on Midline1 protein complex, which is 
implicated in translation of various protein 
complexes involved in neurodegeneration 
(Aranda-Orgilles et al., 2011; Krauss et al., 
2013). Metformin interferes with assembly 
of Midline1 protein complex thereby reduc-
ing translation of BACE 1 mRNA which in 
turn decreases Aβ production and tau-
phosphorylation (Kickstein et al., 2010). 
Thus, Metformin is being explored as suita-
ble drug in treatment of AD since it targets 
both Aβ production and tau-phosphorylation 
which are hallmarks of the disease. Moreo-
ver it appears to be less harmful even if it 
suppresses the translation of multiple 
mRNAs regulated by Midline1, as it is al-
ready being used as ADD. 
 
Thiazolidinediones (Rosiglitazone and 
Pioglitazone) 
Thiazolidinediones are stimulators of pe-
roxisome proliferator activated receptor 
gamma (PPARγ) and apart from having anti 
diabetic potentials also appear to have anti-
amyloidogenic, anti-inflammatory, and insu-
lin sensitizing effects, thus signifying the 
role in delaying and reducing the risk of neu-
rodegeneration (Heneka et al., 2001). Neuro-
protection is provided by lowering peripheral 
insulin and enhancing insulin sensitivity, re-
ducing inflammation and Aβ accumulation 
and also by increasing cerebral blood flow 
(Sato et al., 2011; Landreth, 2007). Potential 
role in treatment of AD include reductions in 
inflammatory cytokines (Heneka et al., 
2005), oxidative stress (Nicolakakis et al., 
2008), Aβ deposits (Heneka et al., 2005), 
glial activation (Nicolakakis et al., 2008), tau 
phosphorylation (To et al., 2011), and gluco-
corticoid signaling (Escribano et al., 2009; 
Garcia-Bueno et al., 2005). Thiazolidinedi-
ones also improve cognition independent of 
their effect on glucose regulation as shown 
in the Tg2576 model of AD with diabetes 
(Rodriguez-Rivera et al., 2011).  
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Rosiglitazone have protective role 
against neuronal insulin resistance induced 
by Aβ oligomers (De Felice et al., 2009). 
They are shown to increase brain Insulin-
degrading enzyme levels in an animal model 
of AD (Pedersen et al., 2006). Watson and 
colleagues (2005) conducted a study on pa-
tients with mild to moderate AD and showed 
that in patients without ApoE ε4 allele there 
was improvement in cognition and modula-
tion of Aβ levels in cerebral spinal fluid 
while patients with ApoE ε4 did not respond 
to the drug (Rosiglitazone) and showed no 
improvement. Possible explanation could be 
role of drug on mitochondria in the brain 
thereby increasing their metabolic efficiency 
and number (Craft et al., 2006). Encouraging 
preliminary data based on smaller pilot stud-
ies led to sponsoring of phase 3 studies of 
rosiglitazone in AD but unfortunately larger 
trials could not replicate positive findings 
(Harrington et al., 2009).  
The possible role of oxidative stress in 
the pathogenesis of AD has been highlighted 
recently (Calissano et al., 2009). Activation 
of microglia in AD results in production of 
large quantities of free radicals including 
peroxynitrite formed due to interaction of 
NO with oxygen (Murphy, 2000). Ji and col-
leagues (2010) showed that the levels of NO 
produced by proinflammatory mediators in 
cultured microglial cells can be reduced by 
treatment with PPAR-γ agonists. Similarly, 
Heneka and colleagues (2005) concluded 
that iNOS expression in cerebellum can be 
suppressed by troglitazone and pioglitazone 
(Figure 3) thus protecting granule cells 
against lipopolysaccharide/ interferon-γ in-
sult. Pioglitazone are thought to act as scav-
engers of free radicals and peroxynitrate in 
the sera of AD patients (Ceconi et al., 2007). 
Gray (2012) discussed the role of pioglita-
zone as xeno protective agent in vitro. In an-
other study, the triple transgenic mouse 
model of AD with accelerated Aβ deposition 
and tau pathology was treated with the 
pioglitazone (18 mg/Kg body weight/day). 
After four months, treated animals exhibited 
improved learning on the active avoidance 
task, decreased hippocampal Aβ and tau de-
posits, and enhanced short- and long-term 
plasticity. Surprisingly, peripheral glucose 
concentrations were not altered suggesting 
that pioglitazone acted, at least in part, 
through mechanisms other than glucose reg-
ulation (Murphy et al., 2012). 
 
INSULIN SECRETAGOGUES 
Third-Generation Sulfonylureas 
(Glimepiride) 
Glimepiride (Figure 4) binds to the sul-
fonylurea receptor SUR1 present on the pan-
creatic cells membrane which in turns stimu-
lates insulin secretion by closing potassium 
channel (Farret et al., 2005). It is also report-
ed to have other extra pancreatic effects like 
increasing glucose uptake, stimulating the re-
lease of GPI-anchored proteins and activat-
ing PPARγ (Fukuen et al., 2005). Reportedly 
it docks to PPARγ and exhibits PPARγ ago-
nistic activity in cell-based transactivation 
assay (Scarsi et al., 2007). It also enhances 
the interaction of PPARγ with cofactors and 
up regulates the expressions of PPARγ target 
genes, including aP2 and leptin (Fukuen et 
al., 2005). PPARγ activation is demonstrated 
to decrease levels of Aβ and senile plaques 
which improves the cognitive function in AD 
 
 
 
Figure 3: Structure of Pioglitazone 
 
 
 
Figure 4: Structure of Glimepiride 
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patients (Jiang et al., 2008). Due to similarity 
in structure with BACE-1 inhibitor sulfona-
mide it is indicated that glimepiride possess 
BACE-1 inhibition properties and thus down 
regulates Aβ. Apart from glimepiride another 
sulfonylurea drug glipizide, enhances cogni-
tive function of T2DM patients (Testa and 
Simonson, 1998). Results of study conducted 
by Liu and colleagues (2013) show reduce 
production of Aβ in primary cortical neurons 
which were attributed to suppression of 
BACE1 activity and down regulation of 
BACE1 mRNA and protein expression. The 
result appears more promising and highlights 
the future role of glimepiride in treatment of 
AD associated with diabetes in lieu of fact 
that hyperglycemia enhances Aβ 40 produc-
tion and glimepiride significantly lowers hy-
perglycemia induced Aβ 40 production. 
 
PEPTIDE ANALOGS 
Insulin like metabolic hormones like 
Glucagon-like peptide-1 (GLP-1) and Amy-
lin A (structurally unrelated to insulin and 
binding to independent receptors in brain) 
provide another opportunity to restore insu-
lin signaling in the AD brain. Analogs of 
these two hormones are approved or are in 
the process of regulatory approval in the 
USA. The signaling pathways activated by 
them converge and facilitate insulin signal-
ing. They readily cross the BBB. Since they 
do not cause significant hypoglycemia (as 
opposed to insulin), thus can be safely ad-
ministered at relatively high doses peripher-
ally.  
The hormone GLP-1 (secreted by intesti-
nal L cells in response to a meal) lowers glu-
cose by various mechanisms like increasing 
insulin secretion, decreasing glucagon secre-
tion, delayed gastric emptying, increased sa-
tiety, and increased insulin sensitivity in 
multiple tissues (American Diabetes Associ-
ation, 2013). The GLP-1 receptor is nearly 
ubiquitous and is widely expressed in the 
brain. Since dipeptidyl peptidase-4 (DPP-4) 
rapidly degrades endogenous GLP-1 thus for 
treatment of T2DM injectable analogs of 
GLP-1 (exenatide and liraglutide) with pro-
longed half-lives have been developed and 
approved. Multiple oral inhibitors of DPP-4 
that indirectly augment endogenous GLP-1 
levels have also been approved for T2DM. 
Studies conducted in cell culture and mouse 
models of AD using GLP1 have shown en-
couraging results (McClean et al., 2011). 
These agents provide protection against oxi-
dative injury and also cause synaptogenesis 
and neurogenesis thus acting as growth fac-
tor in brain. There were two pilot studies 
conducted of GLP-1 analogs for AD (3-year 
230-patient randomized trial using exenatide 
sponsored by National Institute on Aging 
(Clinical Trials identifier: NCT01255163) 
and a 12-month, 200-patient trial of lirag-
lutide conducted by the Imperial College 
London (Clinical Trials identifier: 
NCT01843075)). In AD mouse models, 
GLP-1 agonists are shown to improve 
memory behaviors, reduce levels of AD 
pathologic markers (oligomeric Aβ and Aβ 
plaque load) and decrease activation of mi-
croglia. 
Amylin (islet amyloid polypeptide), is a 
peptide hormone co-secreted with insulin 
from β-cells of pancreas (Mitsukawa et al., 
1990) and lowers blood glucose levels (like 
GLP-1) through delayed gastric emptying, 
decreased glucagon secretion, and increased 
satiety (Gedulin et al., 1997). Utility of en-
dogenous amylin is limited due to its pro-
pensity to aggregate and form amylin oligo-
mers and plaques. Recently in Alzheimer’s 
brain tissue abnormal Amylin has been rec-
ognized. Jackson and colleagues (2013) re-
ported oligomeric and plaque-like accumula-
tions of Amylin in brain parenchyma and 
cerebral vasculature of diabetics as well as 
non diabetic AD patients. Interestingly, these 
plaques though independent were sometimes 
co localized with Aβ plaques. Recently, in a 
rodent model of accelerated aging an amylin 
agonist has been investigated as a potential 
therapeutic approach for the treatment of AD 
(Adler et al., 2014).  
Amylin readily crosses the BBB (Banks 
et al., 1995), and its receptors are distributed 
widely throughout the brain (area postrema, 
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nucleus of the solitary tract, parabrachial nu-
cleus, amygdala, hypothalamus, nucleus ac-
cumbens, and dorsal raphe (Sexton et al., 
1994)) thus, it is thought to have widespread 
implications in variety of CNS functions 
(like memory, mood, anxiety and satiety). 
Amylin interacts with signaling cascade in 
peripheral tissue and CNS which activates 
several downstream targets of insulin like 
signal transducer and activator of transcrip-
tion 3, AMP-activated protein kinase, and 
Akt cascades involved in cellular metabo-
lism and survival (Moon et al., 2011; Mihay-
lova and Shaw, 2011). Amylin is also a 
known modulator of the extracellular-signal-
regulated kinases/mitogen-activated protein 
Kinase pathway which effects satiety and is 
thought to play a role in synaptic plasticity 
and memory consolidation in the hippocam-
pus (Potes et al., 2012). Adler and colleagues 
(2014) reported an improved memory per-
formance in the novel object recognition task 
and modulation of synapses, decrease oxida-
tive stress and inflammatory markers in the 
hippocampus of mice following chronic in-
fusion of pramlintide (soluble, non aggregat-
ing synthetic analog of amylin), in mice. 
Morley and colleagues (2012) demonstrated 
the direct effects of amylin on cognition and 
AD pathogenesis by showing the effects of 
pramlintide on memory in senescence-
accelerated prone (SAMP8) mouse (model 
of sporadic AD), the results indicated re-
duced expression of HO-1 (cellular stress 
protein that is activated during high oxida-
tive stress and inflammatory states). Expres-
sion of HO-1 is increased in the hippocam-
pus and cerebral cortex of AD brains (Schip-
per et al., 1995) and age-dependant increase 
in the SAMP8 mouse (Cuesta et al., 2010). 
Pramlintide decreases HNE which is a by-
product of lipid peroxidation and act as early 
stress marker in AD brain (Sayre et al., 
1997), it also reduces COX-2 (marker of in-
flammation) which increases in AD as well 
as in brain with aging (Ho et al., 1998). Oth-
er studies have also reported beneficial role 
of pramlintide in oxidative stress and in-
flammation in peripheral tissues (Ceriello et 
al., 2005). It is worth noting that Pramlintide 
causes minimal hypoglycemia, and its excel-
lent safety profile and tolerability are appeal-
ing for the study and treatment of AD. 
 
Injectable Glucagon-like peptide analogs 
and agonists  
GLP-1 is an endogenous 30-amino acid 
peptide hormone. Neuroprotective role GLP-
1 analogues have been shown in various in 
vitro and in vivo studies. GLP-1 receptors are 
expressed in the hippocampal area (im-
portant site of neurogenesis in adults and 
role in cognition and memory). The neuro-
protective functions of GLP-1 analogues can 
be realized only if they cross BBB and bind 
to their receptors. In fact many novel long-
lasting GLP-1 receptor agonists have been 
developed in recent years like Exendin-4 
(Byetta), Liraglutide (Victoza) and lix-
isenatide (Lyxumia) (Christensen et al., 
2011; Faludi et al., 2009). 
GLP-1 acting as a growth factor in the 
brain has been shown to induce neurite out-
growth and protect against oxidative injury 
in cultured neuronal cells (Perry et al., 2007). 
Increased neurite growth and improvement 
in learning was shown in mice which over 
expressed GLP-1 receptors in hippocampus 
(During et al., 2003). Abbas and colleagues 
(2009) reported impairments in long-term 
potentiation of synaptic transmission in the 
hippocampus and learning of new tasks upon 
deletion of GLP-1 receptor. Widespread ef-
fects of GLP-1 and analogs have been re-
ported. Reductions in endogenous levels of 
Aβ in the brain have been reported upon use 
of GLP-1 and exendin-4 (Perry et al., 2003). 
Proliferation of neuronal progenitor cells in 
the brain of mice is induced by GLP-1 ana-
logs (During et al., 2003). It is interesting to 
note that AD patients could benefit due to 
increase in cell proliferation which facilitates 
repair of neuronal networks in cortical tissue 
(Greenberg and Jin, 2006). Gengler and col-
leagues (2012) reported long-term potentia-
tion in the hippocampus when Val(8) GLP-1 
was injected intraperitoneally for 3 weeks. 
Reported results are encouraging and GLP-1 
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analogs could prove beneficial in improving 
cognition, neuronal communication and re-
generation of neurons in AD patients 
(Holscher and Li, 2010).  
Peripheral injection of liraglutide in-
creases neuronal progenitor cell proliferation 
and neurogenesis in the brain (Hamilton et 
al., 2011). It is a known fact that detrimental 
long-term effects of inflammation are one of 
the important underlying mechanisms of 
neurodegeneration in AD (Aisen, 2002). 
Jankowsky and colleagues (2001) injected li-
raglutide (which crosses the BBB) intraperi-
toneally in mouse model of AD for 8 weeks 
and demonstrated the improvements in learn-
ing (object recognition and water maze 
tasks) which were supported by a significant 
protection of long-term potentiation and 
paired-pulse facilitation. In the same model 
the reduction in synaptic numbers was partly 
prevented by the drug which in turn im-
proves cognitive functions. The results as-
sume further importance when it was shown 
that the drug reduces amyloid synthesis. Im-
portantly, in liraglutide treated model in-
flammatory responses in the brain (evaluated 
by the number of activated microglia) were 
less and the number of new neurons in the 
dentate gyrus was normalized to wild-type 
control levels. 
Agents like dipeptidyl peptidase-4 (DPP-
4) inhibitors increase the levels of glucagon-
like peptide-1 (GLP-1) and can act as suita-
ble disease modifying agents in the treatment 
of AD. In a recent study done by Kosaraju 
(2013), treatment of rat models induced with 
AD (by intracerebral injection of STZ) with 
Vildagliptin (DPP-4 inhibitor) showed dose 
and time-dependent improvements in 
memory retention and dose-dependent atten-
uation of Aβ, tau phosphorylation and in-
flammatory markers thus indicating that with 
increase in GLP-1 levels there is clearance of 
Aβ and tau which is beneficial in AD. 
 
GLYCOSURICS 
SGLT-2 inhibitors (Canagliflozin and 
Dapagliflozin) 
Sodium glucose co-transporters (SGLTs 
1 and 2) cause renal glucose reabsorption 
(mostly by SGLT-2) (Rajesh et al., 2010). 
Since SGLT-2 is expressed exclusively in 
kidney thus its inhibition act as a therapeutic 
target in T2DM without risk of hypoglyce-
mia since it increases renal excretion of glu-
cose without influencing insulin secretion 
(Edward and Robert, 2010). In fact, both pre 
and postprandial blood glucose levels are re-
duced on acute administration and there is 
decrease glucotoxicity on chronic admin-
istration of SGLT inhibitors (Bakris et al., 
2009). Recently, two SGLT-2 inhibitor drugs 
have been approved by Food and Drug Ad-
ministration (FDA), namely “Invokana” 
(chemically known as canagliflozin) (Figure 
5) and “Forxiga” (chemically known as 
Dapagliflozin) (Figure 6). Recent studies by 
Rizvi et al. (2014) and Shaikh et al. (2014) 
have explored the molecular interactions of 
human brain acetylcholinesterase with these 
antidiabetic drugs. Results suggest that these 
might act as inhibitor of acetylcholinesterase 
and SGLT2. However, further investigations 
are needed to address the issue regarding 
their dual inhibitory roles against T2DM and 
AD. 
 
 
 
Figure 5: Structure of Canagliflozin 
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Figure 6: Structure of Dapagliflozin 
 
 
CONCLUSIONS 
Diabetes and AD have traditionally been 
thought to be independent disorders. Howev-
er, the results of recent investigations and re-
searches have suggested possible interactions 
which could lead to effective common treat-
ment regimes. Many clinical trials are un-
derway to test effectiveness of ADD target-
ing brain insulin signaling in AD patients. 
The complexity of the task at hand and chal-
lenges in improving brain functions includ-
ing cognition have made the work more in-
teresting specially as far as testing “AD-
T2DM hypothesis” is concerned. The results 
of these trails will give an insight into the 
mechanisms which connect these two pro-
gressive and challenging diseases affecting 
mankind and will also add new chapters in 
pharmacotherapy. 
 
Conflict of interest 
The authors confirm that this article con-
tent has no conflict of interest. 
 
Acknowledgements 
Sibhghatulla Shaikh is supported by IN-
SPIRE grant from Department of Science & 
Technology (DST), New Delhi, India (Grant 
Number: IF130056), which is sincerely 
acknowledged. Shazi Shakil thanks all of the 
staff of Center of Innovation in Personalized 
Medicine (CIPM), King Abdulaziz Universi-
ty, Saudi Arabia for continued support. 
 
 
 
REFERENCES 
Abbas T, Faivre E, Holscher C. Impairment of synap-
tic plasticity and memory formation in GLP-1 recep-
tor KO mice: interaction between type 2 diabetes and 
Alzheimer’s disease. Behav Brain Res. 2009;205:265-
71. 
Adler BL, Yarchoan M, Hwang HM, Louneva N, 
Blair JA, Palm R, et al. Casadesus G Neuroprotective 
effects of the amylin analogue pramlintide on Alz-
heimer’s disease pathogenesis and cognition. Neuro-
biol Aging. 2014;35:793-801. 
Aisen PS. The potential of anti-inflammatory drugs 
for the treatment of Alzheimer’s disease. Lancet Neu-
rol. 2002;1:279-84. 
Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, 
Raffa RB. Diabetes mellitus and Alzheimer's disease: 
shared pathology and treatment? Br J Clin Pharmacol. 
2011;71:365-76. 
Allam AR, Sridhar GR, Thota H, Babu CS, Prasad 
AS, Divakar C. Alzheimer's disease and type 2 diabe-
tes mellitus: the cholinesterase connection? Lipids 
Health Dis. 2006;5:28. 
American Diabetes Association. Standards of medical 
care in diabetes - 2013. Diabetes Care. 2013;36:11-
66. 
Aranda-Orgilles B, Rutschow D, Zeller R, Karagian-
nidis AI, Kohler A, Chen C, et al. Protein phosphatase 
2A (PP2A)-specific ubiquitin ligase MID1 is a se-
quence-dependent regulator of translation efficiency 
controlling 3-phosphoinositide- dependent protein ki-
nase-1 (PDPK-1). J Biol Chem. 2011;286:39945-57. 
Bakris GL, Fonseca VA, Sharma K, Wright EM. Re-
nal sodium glucose transport: role in diabetes and po-
tential clinical implications. Kidney Int. 2009;75: 
1272-7. 
Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan 
JB. Permeability of the blood-brain barrier to amylin. 
Life Sci. 1995;57:1993-2001. 
Biessels GJ, Deary IJ, Ryan CM. Cognition and dia-
betes: A lifespan perspective. Lancet Neurol. 2008;7: 
184-90.  
Calissano P, Matrone C, Amadoro G. Apoptosis and 
in vitro Alzheimer disease neuronal models. Commun 
Integr Biol. 2009;2:163-9.  
Carrotta R, Di Carlo M, Manno M, Montana G, 
Picone P, Romancino D, et al. Toxicity of recombi-
nant beta-amyloid prefibrillar oligomers on the mor-
phogenesis of the sea urchin Paracentrotus lividus. 
FASEB J. 2006;20:1916-7. 
EXCLI Journal 2015;14:684-696 – ISSN 1611-2156 
Received: April 01, 2015, accepted: May 05, 2015, published: May 19, 2015 
 
 
693 
Ceconi C, Francolini G, Bastianon D, Gitti GL, 
Comini L, Ferrari R. Differences in the effect of angi-
otensin-converting enzyme inhibitors on the rate of 
endothelial cell apoptosis: In vitro and in vivo studies. 
Cardiovasc Drugs Ther. 2007;21:423-9. 
Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel 
CA, Ruggles JA, et al. Effects of pramlintide on post-
prandial glucose excursions and measures of oxida-
tive stress in patients with type 1 diabetes. Diabetes 
Care. 2005;28:632-7. 
Cernea S, Raz I. Intranasal insulin: PK profile de-
signed specifically for prandial treatment of Type 2 
Diabetes. Drugs Today. 2006;42:405-24. 
Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, 
et al. Antidiabetic drug metformin (GlucophageR) in-
creases biogenesis of Alzheimer’s amyloid peptides 
via up-regulating BACE1 transcription. Proc Natl 
Acad Sci USA. 2009;106:3907-12. 
Christensen M, Knop FK, Vilsboll T, Holst JJ. Lix-
isenatide for type 2 diabetis mellitus. Expert Opin In-
vestig Drugs. 2011;20:549-57. 
Craft S, Saunders AM, Altman JF, Ormandy GC, 
Craft S, Foley IM, et al. Rosiglitazone in Alzheimer's 
Disease Study Group. Efficacy of rosiglitazone in a 
genetically defined population with mild-to-moderate 
Alzheimer's disease. Pharmacogenomics J. 2006;6: 
246-54. 
Craft S, Baker LD, Montine TJ, Minoshima S, Wat-
son GS, Claxton A, et al. Intranasal insulin therapy 
for Alzheimer disease and amnestic mild cognitive 
impairment: a pilot clinical trial. Arch Neurol. 2012; 
69:29-38. 
Cuesta S, Kireev R, Forman K, García C, Escames G, 
Ariznavarreta C, et al. Melatonin improves inflamma-
tion processes in liver of senescence-accelerated 
prone male mice (SAMP8). Exp Gerontol. 2010;45: 
950-6. 
De Felice FG, Vieira MNN, Bomfim TR, Decker H, 
Velasco PT, Lambert MP, et al. Protection of synap-
ses against Alzheimer’s-linked toxins: Insulin signal-
ing prevents the pathogenic binding of Abeta oligo-
mers. Proc Natl Acad Sci USA. 2009;106:1971-6. 
Di Carlo M, Picone P, Carrotta R, Giacomazza D, San 
Biagio PL. Insulin promotes survival of amyloid-beta 
oligomers neuroblastoma damaged cells via caspase 9 
inhibition and Hsp70 upregulation. J Biomed Bio-
technol. 2010;2010:8. 
During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons 
HL, Jiao X, et al. Glucagon-like peptide-1 receptor is 
involved in learning and neuroprotection. Nat Med. 
2003;9:1173-9. 
Edward CC, Robert RH. SGLT2 inhibition-a novel 
strategy for diabetes treatment. Nat Rev Drug Discov. 
2010;1-9. 
El-Mir MY, Detaille D, Delgado-Esteban M, Guigas 
B, Attia S, Fontaine E, et al. Neuroprotective role of 
antidiabetic drug metformin against apoptotic cell 
death in primary cortical neurons. J Mol Neurosci. 
2008;34:77-87. 
Escribano L, Simon AM, Perez-Mediavilla A, Sala-
zar-Colocho P, Del Rio J, Frechilla D. Rosiglitazone 
reverses memory decline and hippocampal glucocor-
ticoid receptor down-regulation in an Alzheimer’s 
disease mouse model. Biochem Biophys Res Com-
mun. 2009;379:406-10.  
Exalto L, Whitmer R, Kappele L, Biessels G. An up-
date on type 2 diabetes, vascular dementia and Alz-
heimer's disease. Exp Gerontol. 2012;47:858-64. 
Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK. 
The effect of exenatide re exposure on safety and effi-
cacy. Peptides. 2009;30:1771-4. 
Farret A, Lugo-Garcia L, Galtier F, Gross R, Petit P. 
Pharmacological inter-ventions that directly stimulate 
or modulate insulin secretion from pancreatic beta-
cell: implications for the treatment of type 2 diabetes. 
Fundam Clin Pharmacol. 2005;19:647-56. 
Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda 
M, Shimomura I. Sulfonylurea agents exhibit peroxi-
some proliferator-activated receptor gamma agonistic 
activity. J Biol Chem. 2005;280:23653-9. 
Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, 
Lorenzo P, Leza JC. Peroxisome proliferator-activat-
ed receptor gamma activation decreases Neuroin-
flammation in brain after stress in rats. Biol Psychia-
try. 2005;57:885-94.  
Gedulin BR, Rink TJ, Young AA. Dose-response for 
glucagon static effect of amylin in rats. Metabolism. 
1997;46:67-70. 
Gengler S, McClean P, McCurtin R, Gault V, 
Holscher C. Val(8)GLP-1 rescues synaptic plasticity 
and reduces dense core plaques in APP/PS1 mice. 
Neurobiol Aging. 2012;33:265-76. 
Gray E, Ginty M, Kemp K, Scolding N, Wilkins A. 
The PPAR-gamma agonist pioglitazone protects cor-
tical neurons from inflammatory mediators via im-
provement in peroxisomal function. J Neuroinflam-
mation. 2012;9:63. 
EXCLI Journal 2015;14:684-696 – ISSN 1611-2156 
Received: April 01, 2015, accepted: May 05, 2015, published: May 19, 2015 
 
 
694 
Greenberg DA, Jin K. Neurodegeneration and neuro-
genesis: focus on Alzheimer’s disease. Curr Alzhei-
mer Res. 2006;3:25-8. 
Gupta A, Bisht B, Dey CS. Peripheral insulin-sensiti-
zer drug metformin ameliorates neuronal insulin re-
sistance and Alzheimer’s-like changes. Neuropharma-
cology. 2011;60:910-20. 
Hamilton A, Patterson S, Porter D, Gault VA, 
Holscher C. Novel GLP-1 mimetics developed to treat 
type 2 diabetes promote progenitor cell proliferation 
in the brain. J Neurosci Res. 2011;89:481-9. 
Hardy J, Allsop D. Amyloid deposition as the central 
event in the aetiology of Alzheimer’s disease. Trends 
Pharmacol Sci. 1991;12:383-8. 
Harrington C, Sawchak S, Chiang C, Davies J, Saun-
ders A, Irizarry M, et al. Effects of rosiglitazone-
extended release as adjunctive therapy to acetylcho-
linesterase inhibitors over 48 weeks on cognition in 
Apoe4-stratified subjects with mild-to-moderate Alz-
heimer’s disease. Alzheimer Dement. 2009;5:17-8. 
Heneka MT, Landreth GE, Feinstein DL. Role for pe-
roxisome proliferator-activated receptor-gamma in 
Alzheimer’s disease. Ann Neurol. 2001;49:276.  
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke 
A, Dewachter I, Kuiperi C, et al. Acute treatment with 
the PPARgamma agonist pioglitazone and ibuprofen 
reduces glial inflammation and Abeta 1–42 levels in 
APPV717I transgenic mice. Brain. 2005;128:1442-53.  
Hilder TL, Baer LA, Fuller PM, Fuller CA, Grin-
deland RE, Wade CE, et al. Insulin-independent path-
ways mediating glucose uptake in hind limb-suspen-
ded skeletal muscle. J Appl Physiol. 2005;99:2181-8. 
Ho L, Osaka H, Aisen PS, Pasinetti GM. Induction of 
cyclooxygenase (COX)-2 but not COX-1 gene ex-
pression in apoptotic cell death. J Neuroimmunol. 
1998;89:142-9. 
Holscher C, Li L. New roles for insulin-like hormones 
in neuronal signalling and protection: New hopes for 
novel treatments of Alzheimer’s disease? Neurobiol 
Aging. 2010;31:1495-502. 
Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence 
of dementia is increased in type 2 diabetes and re-
duced by the use of sulfonylureas and metformin. J 
Alzheimers Dis. 2011;24:485-93.  
Hwang IK, Kim IY, Joo EJ, Shin JH, Choi JW, Won 
MH, et al. Metformin normalizes type 2 diabetes-
induced decrease in cell proliferation and neuroblast 
differentiation in the rat dentate gyrus. Neurochem 
Res. 2010;35:645-50.  
Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, 
Despa F. Amylin deposition in the brain: A second 
amyloid in Alzheimer disease? Ann Neurol. 2013;74: 
517-26. 
Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, 
Copeland NG, Borchelt DR. Co-expression of multi-
ple trans genes in mouse CNS: a comparison of strat-
egies. Biomol Eng. 2001;17:157-65. 
Ji H, Wang H, Zhang F, Li X, Xiang L, Aiguo S. 
PPARgamma agonist pioglitazone inhibits microglia 
inflammation by blocking p38 mitogen activated pro-
tein kinase signaling pathways. Inflamm Res. 2010; 
59:921-9. 
Jiang Q, Heneka M, Landreth GE. The role of peroxi-
some proliferator-activated receptor-gamma (PPAR-
gamma) in Alzheimer’s disease: therapeutic implica-
tions. CNS Drugs. 2008;22:1-14. 
Kickstein E, Krauss S, Thornhill P, Rutschow D, Zel-
ler R, Sharkey J, et al. Biguanide metformin acts on 
tau phosphorylation via mTOR/protein phosphatase 
2A (PP2A) signaling. Proc Natl Acad Sci USA. 2010; 
107:21830-5. 
Kirpichnikov D, McFarlane SI, Sowers JR. Metfor-
min: an update. Ann Intern Med. 2002;137:25-33. 
Knowler WC, Barrett-Connor E, Fowler SE, Hamman 
RF, Lachin JM, Walker EA, et al. Reduction in the 
incidence of type 2 diabetes with lifestyle intervention 
or metformin. N Engl J Med. 2002;346:393-403. 
Kochanek KD, Xu J, Murphy SL, Minino AM, Kung 
HC. Deaths: Preliminary data for 2009. Natl Vital Stat 
Rep. 2011;59:1-51. 
Kosaraju J. Neuroprotective effects of vildagliptin, a 
dipeptidyl peptidase 4 inhibitor against streptozotocin 
induced Alzheimer’s disease. J Neurol Neurophysiol. 
2013;4:3. 
Krauss S, Griesche N, Jastrzebska E, Chen C, 
Rutschow D, Achmüller C, et al. Translation of HTT 
mRNA with expanded CAG repeats is regulated by 
the MID1-PP2A protein complex. Nat Commun. 
2013;4:1511. 
Łabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, 
Okopień B. Quantification of metformin by the HPLC 
method in brain regions, cerebrospinal fluid and plas-
ma of rats treated with lipopolysaccharide. Pharmacol 
Rep. 2010;62:956–65. 
Landreth G. Therapeutic use of agonists of the nuclear 
receptor PPARγ in Alzheimer’s disease. Curr Alz-
heimer Res. 2007;4:159-64.  
EXCLI Journal 2015;14:684-696 – ISSN 1611-2156 
Received: April 01, 2015, accepted: May 05, 2015, published: May 19, 2015 
 
 
695 
Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW. 
The insulin/Akt signaling pathway is targeted by in-
tracellular beta amyloid. Mol Biol Cell. 2009;20: 
1533-44. 
Li L, Holscher C. Common pathological processes in 
Alzheimer disease and type 2 diabetes: a review. 
Brain Res Rev. 2007;56:384-402. 
Liu F, Wang Y, Yan M, Zhang L, Pang T, Liao H. 
Glimepiride attenuates Aβ production via suppressing 
BACE1 activity in cortical neurons. Neurosci Lett. 
2013;557:90-4. 
McClean PL, Parthsarathy V, Faivre E, Hölscher C. 
The diabetes drug liraglutide prevents degenerative 
processes in a mouse model of Alzheimer’s disease. J 
Neurosci. 2011;31:6587-94. 
Messier C, Gagnon M. Cognitive decline associated 
with dementia and type 2 diabetes: The interplay of 
risk factors. Diabetologia. 2009;52:2471-4. 
Mielke JG, Taghibiglou C, Wang YT. Endogenous 
insulin signaling protects cultured neurons from oxy-
gen-glucose deprivation-induced cell death. Neurosci-
ence. 2006;143:165-73.  
Mihaylova MM, Shaw RJ. The AMPK signalling 
pathway coordinates cell growth, autophagy and me-
tabolism. Nat Cell Biol. 2011;13:1016-23. 
Mitsukawa T, Takemura J, Asai J, Nakazato M, Kan-
gawa K, Matsuo H, et al. Islet amyloid polypeptide 
response to glucose, insulin, and somatostatin ana-
logue administration. Diabetes. 1990;39:639-42. 
Moon HS, Chamberland JP, Diakopoulos KN, Fio-
renza CG, Ziemke F, Schneider B, et al. Leptin and 
amylin act in an additive manner to activate overlap-
ping signaling pathways in peripheral tissues: in vitro 
and ex vivo studies in humans. Diabetes Care. 
2011;34:132-8. 
Morley JE, Farr SA, Kumar VB, Armbrecht HJ. The 
SAMP8 mouse: a model to develop therapeutic inter-
ventions for Alzheimer’s disease. Curr Pharm Des. 
2012;18:1123-30. 
Murphy S. Production of nitric oxide by glial cells: 
Regulation and potential roles in the CNS. Glia. 
2000;29:1-13.  
Murphy MP, Chen KC, Blalock EM, Landfield PW, 
Porter NM, Thibault O. Long-term pioglitazone treat-
ment improves learning and attenuates pathological 
markers in a mouse model of Alzheimer’s Disease. J 
Alzheimers Dis. 2012;30:943-61. 
Nath N, Khan M, Paintlia MK, Singh I, Hoda MN, 
Giri S. Metformin attenuated the autoimmune disease 
of the central nervous system in animal models of 
multiple sclerosis. J Immunol. 2009;182:8005-14. 
Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, 
Fernandes P, Rosa-Neto P, et al. Complete rescue of 
cerebrovascular function in aged Alzheimer’s disease 
transgenic mice by antioxidants and pioglitazone, a 
peroxisome proliferator-activated receptor gamma ag-
onist. J Neurosci. 2008;28:9287-96. 
Nolte MS, Taboga C, Salamon E, Moses A, Longe-
necker J, Flier J, et al. Biological activity of nasally 
administered insulin in normal subjects. Horm Metab 
Res. 1990;22:170-4.  
Park S. A common pathogenic mechanism linking 
type-2 diabetes and Alzheimer's disease: evidence 
from animal models. J Clin Neurol. 2011;7:10-8. 
Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, 
Craft S, Haynatzki GR. Rosiglitazone attenuates 
learning and memory deficits in Tg2576 Alzheimer 
mice. Exp Neurol. 2006;199:265-73. 
Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson 
MP, Egan JM, et al. Glucagon-like peptide-1 decreas-
es endogenous amyloid-beta peptide (Abeta) levels 
and protects hippocampal neurons from death induced 
by Abeta and iron. J Neurosci Res. 2003;72:603-12. 
Perry T, Holloway HW, Weerasuriya A, Mouton PR, 
Duffy K, Mattison JA, et al. Evidence of GLP-1-
mediated neuroprotection in an animal model of pyri-
doxine-induced peripheral sensory neuropathy. Exp 
Neurol. 2007;203:293-301. 
Picone P, Carrotta R, Montana G, Nobile MR, San 
Biagio PL, Di Carlo M. Abeta oligomers and fibrillar 
aggregates induce different apoptotic pathways in 
LAN5 neuroblastoma cell cultures. Biophys J. 2009; 
96:4200-11. 
Picone P, Giacomazza D, Vetri V, Carrotta R, Militel-
lo V, San Biagio PL, et al. Insulin-activated Akt res-
cues Aβ oxidative stress-induced cell death by orches-
trating molecular trafficking. Aging Cell. 2011;10: 
832-43. 
Potes CS, Boyle CN, Wookey PJ, Riediger T, Lutz 
TA. Involvement of the extracellular signal-regulated 
kinase 1/2 signaling pathway in amylin’s eating inhib-
itory effect. Am J Physiol Regul Integr Comp Physiol. 
2012;302:340-51. 
EXCLI Journal 2015;14:684-696 – ISSN 1611-2156 
Received: April 01, 2015, accepted: May 05, 2015, published: May 19, 2015 
 
 
696 
Priyadarshini M, Kamal MA, Greig NH, Realef M, 
Abuzenadah AM, Chaudhary AG, et al. Alzheimer's 
disease and type 2 diabetes: exploring the association 
to obesity and tyrosine hydroxylase. CNS Neurol 
Disord Drug Targets. 2012;11:482-9. 
Rajesh R, Naren P, Vidyasagar S, Unnikrishnan M, 
Pandey S, Varghese M. Sodium Glucose Co trans-
porter 2 (SGLT2) inhibitors: a new sword for the 
treatment of Type 2 Diabetes Mellitus. Int J Pharm 
Sci Res. 2010;1:139-47. 
Rensink AA, Otte-Holler I, de Boer R, Bosch RR, ten 
Donkelaar HJ, de Waal RM, et al. Insulin inhibits 
amyloid beta- induced cell death in cultured human 
brain pericytes. Neurobiol Aging. 2004;25:93-103. 
Rizvi SMD, Shakil S, Biswas D, Shakil S, Shaikh S, 
Bagga P, et al. Invokana (Canagliflozin) as a dual in-
hibitor of Acetylcholinesterase and Sodium Glucose 
Co-Transporter 2: advancement in Alzheimer’s Dis-
ease-Diabetes Type 2 linkage via an Enzoinformatics 
study. CNS Neurol Disord Drug Targets. 2014;13: 
447-51. 
Rodriguez-Rivera J, Denner L, Dineley KT. Rosig-
litazone reversal of Tg2576 cognitive deficits is inde-
pendent of peripheral gluco-regulatory status. Behav 
Brain Res. 2011;216:255-61.  
Ronnemaa E, Zethelius B, Sundelöf J, Sundström J, 
Degerman-Gunnarsson M, Berne C, et al. Impaired 
insulin secretion increases the risk of Alzheimer dis-
ease. Neurology. 2008;71:1065-71.  
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, 
Iwamoto T. Efficacy of PPAR-gamma agonist piogli-
tazone in mild Alzheimer disease. Neurobiol Aging. 
2011;32:1626-33.  
Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon 
RG, Smith MA. 4- Hydroxynonenal-derived advanced 
lipid peroxidation end products are increased in Alz-
heimer’s disease. J Neurochem. 1997;68:2092-7. 
Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, 
Albrecht H, et al. Sulfonylureas and glinides exhibit 
peroxisome proliferator-activated receptor gamma ac-
tivity: a combined virtual screening and biological as-
say approach. Mol Pharmacol. 2007;71:398-406. 
Schipper HM, Cissé S, Stopa EG. Expression of heme 
oxygenase-1 in the senescent and Alzheimer-diseased 
brain. Ann Neurol. 1995;37:758-68. 
Sexton PM, Paxinos G, Kenney MA, Wookey PJ, 
Beaumont K. In vitro autoradiographic localization of 
amylin binding sites in rat brain. Neuroscience. 1994; 
62:553-67. 
Shaikh S, Rizvi SMD, Shakil S, Riyaz S, Biswas D, 
Jahan R. Forxiga (Dapagliflozin): Plausible role in the 
treatment of diabetes associated neurological disor-
ders. Biotechnol Applied Biochem. 2014; [epub ahead 
of print] DOI:10.1002/bab.1319. 
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, 
Tavares R, et al. Impaired insulin and insulin-like 
growth factor expression and signaling mechanisms in 
Alzheimer’s disease – is this type 3 diabetes? J Alz-
heimers Dis. 2005;7:63-80.  
Testa MA, Simonson DC. Health economic benefits 
and quality of life during improved glycemic control 
in patients with type 2 diabetes mellitus: a random-
ized, controlled, double-blind trial. JAMA. 1998;280: 
1490-6. 
To AW, Ribe EM, Chuang TT, Schroeder JE, Love-
stone S. The epsilon3 and epsilon4 alleles of human 
APOE differentially affect tau phosphorylation in hy-
per insulinemic and pioglitazone treated mice. PLoS 
One. 2011;6:e16991.  
Watson GS, Cholerton BA, Reger MA, Baker LD, 
Plymate SR, Asthana S, et al. Preserved cognition in 
patients with early Alzheimer disease and amnestic 
mild cognitive impairment during treatment with 
rosiglitazone: a preliminary study. Am J Geriatr Psy-
chiatry. 2005;13:950-8.  
Whitmer RA, Gustafson DR, Barrett-Connor E, Haan 
MN, Gunderson EP, Yaffe K. Central obesity and in-
creased risk of dementia more than three decades lat-
er. Neurology. 2008;71:1057-64.  
Wisniewski HM, Frackowiak J. Differences between 
the pathogenesis of senile plaques and congophilic 
angiopathy in Alzheimer disease. J Neuropathol Exp 
Neurol. 1998;57:96-8.  
Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, 
Herscovitz H, et al. AMP-activated protein kinase is 
required for the lipid-lowering effect of metformin in 
insulin-resistant human HepG2 cells. J Biol Chem. 
2004;279:47898-905.  
Zhao WQ, De Felice FG, Fernandez S, Chen H, Lam-
bert MP, Quon MJ, et al. Amyloid beta oligomers in-
duce impairment of neuronal insulin receptors. 
FASEB J. 2008;22:246-60.  
 
